Article

Can retinal ganglion cellular dysfunction reverse itself by IOP decrease after trabeculectomy?

Ganglion cellular dysfunction may reverse itself as the result of a substantial decrease in IOP after trabeculectomy in patients with glaucoma, according to John Mark S. de Leon, MD.

Los Angeles-Ganglion cellular dysfunction may reverse itself as the result of a substantial decrease in IOP after trabeculectomy in patients with glaucoma, according to John Mark S. de Leon, MD.

This finding was based on a study in which Dr. de Leon and colleagues investigated the changes in the visual field threshold sensitivity in the fast and slow components of visual field decay in patients after trabeculectomy.

In case you missed it: Ophthalmology Times announces 2014 Resident Writers Award Program winner

The investigators retrospectively reviewed the visual fields of patients with open-angle glaucoma who had undergone trabeculectomy, explained Dr. de Leon, a research fellow in ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles. Four or more reliable preoperative and postoperative visual field tests were available for all eyes. Patients were included in the study when the last preoperative and first postoperative visual field tests were obtained within 1.5 years of the surgery and when the patients were followed preoperatively and postoperatively for a minimum of 2 years.

Every visual field location was assigned to either fast or slow decay components based on point-wise exponential regression and the decay curves were fit to the sensitivities of the preoperative and postoperative visual field measurements separately. The sensitivity difference between the first postoperative and the last preoperative visual field value at each test location was estimated by the exponential curve fits.

 

The visual field mean deviation (MD) also was fit for the preoperative and postoperative visual fields using linear regression, Dr. de Leon said.

He reported that 71 eyes of 65 patients were followed for an average of 11.9 ± 2.9 years (5.5 ± 2.4 years preoperatively and 5.5 ± 2.4 years postoperatively) and an average of 20.2 ± 8.1 visual fields (10.7 ± 5.9 preoperative visual fields and 9.5 ± 4.7 postoperative visual fields) were obtained.

Postoperatively, investigators observed that the average sensitivity of the fast component locations significantly (p < 0.0001) increased from 20.4 ± 6.1 dB to 22.1 ± 5.4 dB, and the slow component locations significantly (p = 0.004) decreased from 24.7 ± 3.7 dB to 23.9 ± 4.1 dB. For the former, the sensitivity improved (1.74 ± 2.2 dB) but deteriorated (-0.79 ± 2.2 dB) for the latter (p < 0.0001). The average preoperative MD did not differ significantly (p = 0.12) postoperatively (-8.4 ± 5.3 and -9 ± 6.6, respectively).

The investigators observed significant differential effects on the fast and slow components of visual field decay. The sensitivity of the slow component decreased slightly, which was consistent with progressive cataract. In contrast, the sensitivity of the fast visual field component increased significantly, suggesting that retinal ganglion cellular damage may reverse itself after a substantial decrease in IOP, and this may happen more often than considered previously, Dr. de Leon said.

The MD is not sufficiently sensitive to detect such changes in visual field sensitivity, he added.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.